

CERTIFICATE OF ANALYSIS

Retatrutide | 60 mg | Lyophilized Powder

Batch RT60-20260731 | Independently tested by Kovera Labs

ABOUT THIS DOCUMENT

This package contains the full, unedited third-party Certificate of Analysis issued by **Kovera Labs** for the Retatrutide 60 mg batch distributed by **Nova Chems**. The original laboratory report is reproduced in its entirety on the following pages, exactly as issued, in order to preserve chain-of-custody integrity and independent verifiability.

Nova Chems sources this batch through a verified manufacturer supply chain. Third-party laboratory reports may reference the manufacturer or upstream distributor as the sample client. This is standard practice within the research peptide industry, where multiple resellers may draw from the same certified manufacturer lot. The analytical results, methods, and access codes shown on the original report remain fully valid and independently verifiable regardless of the distribution channel.

KEY RESULTS AT A GLANCE

Parameter	Result	Status
Purity (RP-HPLC)	99.353%	PASS
Net Content	63.18 mg	PASS
Identity (LC-MS ESI Q-TOF)	Retatrutide confirmed	PASS
Bacterial Endotoxin (USP <85>)	< 0.03 EU/mL	PASS
Heavy Metals (Pb/As/Cd/Hg, ICP-MS)	All below limits	PASS
Fentanyl / Adulterant Screen	Not Detected	PASS
Sterility Screen	No Growth	PASS

Complete methodology, chromatograms, and quality-control data are included in the attached Kovera Labs report starting on page 2.

HOW TO VERIFY THIS REPORT

Testing Laboratory	Kovera Labs
Report Number	KVR-2026-3A9580
Certified Date	August 13, 2026
Lab Director	Lemar Arghandiwal
Verification Portal	koveralabs.com/verify

Access Codes

7Q61FQB | 74744E | AE7BD9 | 3A9580

Visit **koveralabs.com/verify** and enter report number **KVR-2026-3A9580** with any of the access codes above to independently confirm the authenticity of the signed report, methodology, and raw chromatogram data.

REGULATORY DISCLAIMER

This product is sold strictly **FOR RESEARCH PEPTIDE USE ONLY**. Statements regarding this product have not been evaluated by the FDA or COFEPRIS. Not intended to diagnose, treat, cure, or prevent any disease. Not for human or veterinary use. Handle in accordance with laboratory safety protocols.



Client: Mr Vial

Certified: 08/13/2026

This Certificate of Analysis certifies that the sample listed herein was tested by Kovera Labs using validated analytical methods and was found to meet the stated specifications at the time of analysis.

SAMPLE INFORMATION

Product	Retatrutide	Form	Lyophilized Powder
Batch	RT60-20260731	Labeled Qty	60 mg
Cap Color	Blue	Crimp Color	Silver

TEST RESULTS



	REFERENCE STANDARD	RESULT
Purity	(>98%)	99.353%
Net Content	(~60mg)	63.18 mg
Identity Confirmation (LC-MS)	(Retatrutide)	Retatrutide
Endotoxin Safety Screen	(≤0.5 EU/mL)	PASS
Fentanyl Presence Analysis	(Not Detected)	Not Detected
Rapid Sterility Screening	(No Growth)	No Growth

HEAVY METAL SCREENING

Analyte	Result	Status
Arsenic (As)	Negative	
Cadmium (Cd)	Negative	
Lead (Pb)	Negative	
Mercury (Hg)	Negative	

CHROMATOGRAM

Method: RP-HPLC | Column: C18 | Detection: DAD @ 214 nm



Lamar Arghandinal
Lab Director



koveralabs.com/verify

Report#: KVR-2026-3A9580
Access Code: 7Q61FQB

CLIENT & SAMPLE INFORMATION

Client	Mr Vial	Certified Date	08/13/2026
Product Name	Retatrutide	Strength	60 mg
Lot / Batch	RT60-20260731	Condition	Lyophilized

This Certificate of Analysis certifies that the sample listed herein was tested for bacterial endotoxin using a kinetic chromogenic LAL assay in accordance with USP <85> Bacterial Endotoxins Test.

TEST METHODOLOGY

Test Performed	Quantitative Bacterial Endotoxin Test	Compendial Ref	USP <85>
Assay Type	Kinetic Turbidimetric	Detection λ	660 nm
Detection Range	0.01 - 1.0 EU/mL	Endotoxin Std	E. coli O111:B4
Dilution Vol	2.0 mL	Matrix	LAL Reagent Water

QUANTITATIVE RESULTS

Parameter	Result
Endotoxin Level	< 0.03 EU/mL
Acceptance Limit	≤ 0.5 EU/mL
Sample CV (%)	4.4%
Spike CV (%)	4.3%
Spike Recovery (%)	88%
Final Determination	PASS

CONTROLS

Control	Expected	Observed	Status
Positive Control	Detectable	As expected	Pass
Negative Control	No signal	As expected	Pass

INTERPRETATION

Endotoxin content was quantitatively determined using a kinetic chromogenic LAL assay in accordance with USP <85>. Result reported as below quantitation threshold. The measured endotoxin level meets the specified acceptance criteria. The sample passes the endotoxin limit test.

AUTHORIZATION

REVIEWED BY
Lemar Arghandiwal
Lab Director



CLIENT & SAMPLE INFORMATION

Client	Mr Vial	Certified Date	08/13/2026
Product Name	Retatrutide	Strength	60 mg
Lot / Batch	RT60-20260731	Condition	Lyophilized

ICP-MS metals analysis performed using EPA-referenced methods; results evaluated against internal acceptance criteria.

TEST METHODOLOGY

Test Performed	Elemental Impurities Analysis	Instrument	ICP-MS
Sample Prep	HNO ₃ / H ₂ O ₂ matrix	Calibration	Multi-element standard curve
Internal Std	Sc, Ge, In, Bi	Material Type	Raw Material (Research Use)

ELEMENTAL IMPURITIES RESULTS

Element	Result (ppm)	Acceptance Limit (ppm)	Status
Pb Lead	< 0.5	≤ 10	PASS
As Arsenic	< 0.15	≤ 1.5	PASS
Cd Cadmium	< 0.05	≤ 0.5	PASS
Hg Mercury	< 0.3	≤ 3	PASS

METHOD SUITABILITY (SPIKE RECOVERY)

Element	Spike Level	Recovery	Criteria
Pb Lead	5 ppm	98%	70–150%
As Arsenic	0.75 ppm	102%	70–150%
Cd Cadmium	0.25 ppm	95%	70–150%
Hg Mercury	1.5 ppm	91%	70–150%

Spike recovery confirms method suitability for the sample matrix.

INTERPRETATION

Elemental impurities were determined using ICP-MS with EPA-referenced analytical methods. All tested elements (Pb, As, Cd, Hg) are below the stated acceptance limits. Spike recovery values fall within acceptable ranges, confirming method suitability. The sample meets the stated acceptance criteria for elemental impurities.

QUALITY CONTROL

Method Blank: Pass CCV: Pass Duplicate RPD: < 20%

AUTHORIZATION

REVIEWED BY
Lemar Arghandiwal
Lab Director





CLIENT & SAMPLE INFORMATION

Client	Mr Vial	Sample Name	Retatrutide
Lot Number	RT60-20260731	Date Received	08/09/2026
Certified Date	08/13/2026	Sample Matrix	Lyophilized Powder

TEST METHODOLOGY

RAPID STERILITY SCREENING METHOD

Sample is reconstituted and incubated in growth media under controlled conditions. Cultures are monitored for microbial growth over the incubation period. This rapid screening method provides preliminary sterility assessment and is suitable for quality control purposes. For regulatory compliance, full compendial sterility testing may be required.

TEST RESULTS

TEST PARAMETER	SPECIFICATION	RESULT	STATUS
Bacteria (Aerobic/Anaerobic)	No Growth	No Growth	PASS
Fungi / Yeast	Not Detected	Not Detected	PASS
TEST METHOD Rapid Sterility	INCUBATION PERIOD 2 days	TEMPERATURE 30-35C	


FINAL DETERMINATION



STERILITY SCREEN RESULT

SAMPLE PASSES STERILITY SCREEN

No microbial growth detected during incubation period





Mass Spectrometry Report

LC/MS (ESI Q-TOF) identity confirmation

RETATRUTIDE - PASS - DETECTED

Sample Name : MRV-424602 3A9580 RETA 60mg Compound : Retatrutide
Report ID : KVR-2026-3A9580 Order : MRV-424602
Acquired : 2026-08-13 23:22:36 Polarity : + (ESI)
Expected : 4728.47 Da (monoisotopic) Coverage : 2/9 (22%)



Mass Spectrometry Report

LC/MS (ESI Q-TOF) identity confirmation

Adulterant & Excipient Screen

Presumptive accurate-mass screen of EVERY MS1 scan for common RUO excipients/fillers and controlled-substance adulterants (fentanyl class), matched through $[M+H]^+$, $[M+Na]^+$, $[M+K]^+$, $[M+NH_4]^+$ adducts.

FENTANYL / ADULTERANT SCREEN: NOT DETECTED

Species	Class	Adduct	Target m/z	Obs m/z	RT (min)	Rel %	Scans
Mannitol	Excipient	$[M+Na]^+$	205.068	205.066	0.58	100.0	32
Histidine	Excipient	$[M+Na]^+$	178.059	178.054	0.26	25.8	3
Benzyl alcohol / cresol	Excipient	$[M+K]^+$	147.021	147.021	0.24	11.9	3


SCREEN, NOT CONFIRMATION. Single-stage accurate-mass ESI+ cannot distinguish isobaric compounds without MS/MS. A hit is a presumptive flag; confirm any controlled-substance (fentanyl-class) detection by MS/MS or a reference standard before any release or reporting decision. Absence of a hit does not guarantee absence of an adulterant outside this library or below the screen threshold. Excipient/filler hits are expected in many RUO products (lyoprotectants, buffers, bacteriostatic agents) and are informational.

Mass Spectrometry Report

LC/MS (ESI Q-TOF) identity confirmation

UV / DAD Chromatogram

Diode-array trace acquired on the same injection as the MS data. Channel: 214 nm



No net content or purity is derived from this trace - the Q-TOF DAD carries no reference standards, so it is used for identification support only.